shelf(0)

No. 020 · Metabolic · Fat Loss Peptide

AOD-9604

AOD9604Tyr-hGH(177–191)hGH fragment 176–191 analogue

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint 16 residues
AOD-9604 sequence fingerprint
  • Nonpolar 7
  • Polar 6
  • Positive charge 2
  • Negative charge 1

Each dot is a residue placed around the ring from N- to C-terminus; its distance from the centre reflects its chemistry.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Six randomized, double-blind, placebo-controlled human trials for obesity were run in the 2000s (pooled safety report, Stier et al. 2013); the program did not lead to approval.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Residues
16 amino acids, N→C
Molecular weight
1,815.1 Da
Formula
C78H123N23O23S2
Discovered
2000 Developed from the lipolytic C-terminal domain of hGH at Monash University; first metabolic studies published 2000 (Ng et al.).
Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Sequence

N → C · 16 residues · hover, tap, or use arrow keys to inspect

Note N-terminal Tyr added to human growth hormone residues 177–191; one disulfide bond between C7 and C14.

04

Overview

A modified C-terminal fragment of human growth hormone (Tyr-hGH 177-191) developed as an anti-obesity drug candidate; it was designed to keep GH's lipolytic activity without its growth-promoting or diabetogenic effects.

Research status Six randomized placebo-controlled human trials for obesity completed in the 2000s; never approved as a drug

05

Mechanism

AOD-9604 is human growth hormone residues 177-191 with an added N-terminal tyrosine. It was designed to mimic the lipolytic domain of GH; in obese mice it increased lipolysis and fat oxidation, effects linked to beta-3 adrenergic receptor expression and absent in beta-3 receptor knockout mice. It does not bind the GH receptor.

06

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Stimulated lipolysis in adipose tissue
  • Inhibited lipogenesis
  • No impact on blood glucose or IGF-1
  • Investigated for cartilage repair in an animal model
07

Safety & unknowns

A pooled safety report of six randomized, double-blind, placebo-controlled trials found no effect on serum IGF-1 or glucose tolerance and a tolerability profile similar to placebo. "GRAS" claims refer to self-affirmed status for food use, not an FDA approval or FDA GRAS determination. Not FDA-approved as a drug. Prohibited in sport (WADA S2).

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [2]

  1. Clinical trial 2013

    Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

    Stier H, Vos E, Kenley D. Journal of Endocrinology and Metabolism

    Summary of safety data from six randomized, double-blind, placebo-controlled trials, reporting no effect on IGF-1 or glucose tolerance, no anti-drug antibodies, and tolerability indistinguishable from placebo.

  2. Preclinical 2001

    Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

    Heffernan MA, Thorburn AW, Fam B, et al. International Journal of Obesity and Related Metabolic Disorders

    In obese mice, both hGH and AOD9604 reduced body weight gain and increased fat oxidation and lipolysis, but unlike hGH, AOD9604 did not cause hyperglycaemia or bind the hGH receptor.

    [pubmed] [doi]

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). AOD-9604. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/aod-9604/

$ cite --format=bibtex 
@misc{peptidemeta-aod-9604,
  title = {AOD-9604},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/aod-9604/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open